# Hydroxychloroquine vs Nitazoxanide in Patients With COVID-19

> **NCT04341493** · PHASE4 · TERMINATED · sponsor: **Hugo Mendieta Zeron** · enrollment: 44 (actual)

## Conditions studied

- Coronavirus Infection

## Interventions

- **DRUG:** Nitazoxanide 500 MG
- **DRUG:** Hydroxychloroquine

## Key facts

- **NCT ID:** NCT04341493
- **Lead sponsor:** Hugo Mendieta Zeron
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-04-06
- **Primary completion:** 2020-08-30
- **Final completion:** 2020-12-30
- **Target enrollment:** 44 (ACTUAL)
- **Why stopped:** Concerns about safety of Hydroxychloroquine
- **Last updated:** 2021-04-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04341493

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04341493, "Hydroxychloroquine vs Nitazoxanide in Patients With COVID-19". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04341493. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*